Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

This article explains how stability studies GMP support shelf life justification during inspections. It examines pharmaceutical stability testing, ongoing stability programs, and common GMP inspection observations when expiration date assignment lacks scientific or regulatory support.
GMP did not emerge by chance. This article traces the history of GMP regulations, key enforcement milestones, and regulatory inspection evolution that shaped modern pharmaceutical manufacturing standards and quality systems still used to assess compliance today.
GMP inspections increasingly focus on supplier oversight and audit execution. This article explains how vendor audit programs, supplier qualification, and risk-based evaluation influence inspection outcomes and how inspection-ready audit checklists strengthen GMP supplier control systems.
GMP inspections increasingly rely on documentation quality to judge system control. This article explains how regulators assess GMP records, data integrity, and traceability, and how inspection-ready documentation systems reduce audit findings and escalation risk.
Explore how adverse drug reactions evolve across the pharmacovigilance lifecycle, highlighting post-marketing safety, inspection-sensitive gaps, and structured workflows that ensure regulatory compliance, traceable oversight, and proactive risk management for pharmaceutical teams.
A practical overview of the pharmacovigilance lifecycle, explaining how clinical safety monitoring, signal detection, and risk management planning evolve from pre-marketing activities to post-marketing oversight under current GVP compliance and regulatory inspection expectations.
This article explains why ISO-certified pharmaceutical organizations still face GMP inspection findings, how regulators interpret GMP versus ISO in practice, and what inspection-driven quality oversight requires beyond certification to achieve true regulatory inspection readiness.
Inspection-driven analysis of CSV vs Annex 11 highlighting why validated computerized systems still trigger findings. This article explains regulatory expectations, common inspection gaps, and how governance, data integrity, and lifecycle control shape inspection outcomes in GMP environments